TITLE PAGE.

Title.

Personalized Fluid Management in Patients with Sepsis and AKI: A Policy Tree Approach

Author information.

Wonsuk Oh[1,2], Kullaya Takkavatakarn[1,2,3], Hannah Kittrell[1,4], Khaled Shawwa[5], Hernando

Gomez[6], Ashwin S. Sawant[1,2,7], Pranai Tandon[1,2,8], Gagan Kumar[9], Michael Sterling[10], Ira

Hofer[1,2,11], Lili Chan[1,2,12], John Oropello[13], Roopa Kohli-Seth[13], Alexander W Charney[1,14],

Monica Kraft[8], Patricia Kovatch[4], John A. Kellum[6], Girish N. Nadkarni[1,2,12*], Ankit Sakhuja[1,2,13*]

1.   Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at

Mount Sinai, New York, New York, USA

2.   Division of Data-Driven and Digital Medicine, Department of Medicine, Icahn School of

Medicine at Mount Sinai, New York, New York, USA

3.   Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial

Hospital, Chulalongkorn University, Bangkok, Thailand

4.   Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,

New York, New York, USA

5.   Division of Nephrology, Department of Medicine, West Virginia University, Morgantown,

West Virginia, USA

6.   Department of Critical Care Medicine, School of Medicine, University of Pittsburgh,

Pittsburgh, Pennsylvania, USA

7.   Division of Hospital Medicine, Department of Medicine, Icahn School of Medicine at

Mount Sinai, New York, New York, USA

8.   Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Icahn

School of Medicine at Mount Sinai, New York, New York, USA

9.   Department of Pulmonary and Critical Care Medicine, Northeast Georgia Medical Center,

Gainesville, Georgia, USA

10.   Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine,

Emory University School of Medicine, Atlanta, Georgia, USA

11.   Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of

Medicine at Mount Sinai, New York, New York, USA

12.   Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount

Sinai, New York, New York, USA

13.   Institute for Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York,

New York, USA

14.   Departments of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New

York, USA

* Equal contribution as senior author

Corresponding author:

Ankit Sakhuja, MBBS, MS

Division of Data Driven and Digital Medicine,

Department of Medicine

Icahn School of Medicine at Mount Sinai,

New York, NY

Phone: 212-241-6500, Fax: 212-849-2643

Email: ankit.sakhuja@mssm.edu

Author contributions.

WO and AS designed and conceptualized the study. WO, KT, and HK performed data collection

and analysis. WO and AS interpreted the data analyses. WO and AS wrote the first draft of the

manuscript. All authors critically revised the manuscript for important intellectual content and

read and approved the final version. All authors gave final approval for the version to be

published. WO is first author, GNN and AS and co-senior authors.

Funding.

This work was supported by the National Institutes of Health (NIH) grants K08DK131286

awarded to A.S., R01DK108803, U01HG007278, U01HG009610, and U01DK116100 awarded

to G.N.N. and T32DK007757 and TL1DK136048 awarded to W.O. The content is solely the

responsibility of the authors and does not necessarily represent the views of the NIH.

Running title.

AI guided Fluid Therapy in Sepsis and AKI

Descriptor number.

4.10 Non-Pulmonary Critical Care

Total word count.

3,218 words

Online data supplement.

This article has an online data supplement, which is accessible from this issue's table of content

online at www.atsjournals.org.

ABSTRACT.

Rationale: Intravenous fluids are mainstay of management of acute kidney injury (AKI) after

sepsis but can cause fluid overload. Recent literature shows that restrictive fluid strategy may be

beneficial in some patients with AKI, however, identifying these patients is challenging.

Objectives: We aimed to develop and validate a machine learning algorithm to identify patients

who would benefit from a restrictive fluid strategy.

Methods: We included patients with sepsis who developed AKI within 48 hours of ICU

admission and defined restrictive fluid strategy as receiving <500mL fluids within 24 hours after

AKI. Our primary outcome was early AKI reversal at 24 hours of AKI onset, and secondary

outcomes included sustained AKI reversal and major adverse kidney events by 30 days

(MAKE30). We used a causal forest, a machine learning algorithm to estimate individual

treatment effects and policy tree algorithm to identify patients who would benefit by restrictive

fluid strategy. We developed the algorithm in MIMIC-IV and validated it in SICdb databases.

Measurements and Main Results: Among 2,044 patients in the external validation cohort,

policy tree recommended restrictive fluids for 66.7%. Among these, patients who received

restrictive fluids demonstrated significantly higher rate of early AKI reversal (47.1% vs

31.7%,p=0.004), sustained AKI reversal (28.7% vs 17.5%, p=0.013) and lower rates of

MAKE30 (23.0% vs 37.1%, p=0.011). These results were consistent in adjusted analysis.

Conclusion: Policy tree based on causal machine learning can identify septic patients with AKI

who benefit from a restrictive fluid strategy. This approach needs to be validated in prospective

trials.

The number of words in the abstract.

250 words

Keywords

TEXT.

INTRODUCTION:

Acute kidney injury (AKI) is seen in over one-third of critically ill patients with sepsis

and is associated with worse outcomes(1). Oliguria, a frequent clinical indicator of AKI, is

common in critically ill patients with sepsis who develop AKI(2). It is also the second most

common reason for the administration of intravenous (IV) fluids in critically ill patients(3). Since

the primary emphasis is on volume optimization, IV fluids are a cornerstone in AKI care.

Nonetheless, this approach might not be optimal in all patients. Firstly, administration of fluids

does not consistently translate into a corresponding increase in urine output(4). Secondly,

reliance on fluid therapy increases the risk of fluid accumulation, frequently resulting in fluid

overload. This phenomenon is itself associated with development and exacerbation of AKI(5-7),

and increased mortality rates(7).

Thus, a more personalized approach to IV fluid administration in critically ill patients is

warranted. A restrictive approach to administration of IV fluids in patients with acute lung injury

has shown to be associated with a shorter duration of mechanical ventilation(8). Similarly, a

restrictive fluid approach to resuscitation for septic shock is safe and associated with less fluid

overload(9). More recently, a restrictive approach to use of IV fluids in critically ill patients with

AKI has been shown to be associated with lower cumulative fluid balance and lower rates of

initiation of dialysis(10).

However, it remains challenging to identify specific patients with AKI who would benefit

from a restrictive fluid strategy. We, therefore, conducted this study to identify septic patients

with AKI who would benefit from restrictive fluid therapy.

METHODS:

Study Design and Data Sources

We conducted a retrospective study using data from two critical care databases: the

Medical Information Mart for Intensive Care IV (MIMIC-IV) (11) and the Salzburg Intensive

Care database (SICdb)(12). MIMIC-IV encompasses de-identified electronic health records of

intensive care unit (ICU) patients at Beth Israel Deaconess Medical Center (2008-2022). SICdb

includes de-identified electronic health records from University Hospital Salzburg, Austria

(2013-2021), offering a geographically distinct patient population with different clinical

characteristics from those at Beth Israel Deaconess Medical Center. We used MIMIC-IV for

development and SICdb for external validation. We followed the Strengthening the Reporting of

Observational Studies in Epidemiology (STROBE) guidelines for reporting observational studies

(13).

Study Population

We included adult, critically ill patients with sepsis who developed AKI. Following

Kidney Disease Improving Global Outcomes (KDIGO) guidelines(14), we defined AKI as either

a rise in serum creatinine of 0.3 mg/dL or more within 48 hours or an increase of at least 1.5

times the reference serum creatinine within 7 days, or a urine output of less than 0.5 ml/kg/h for

at least a 6-hour time-period.

To determine reference creatinine, we first identified the baseline creatinine by

calculating the median serum creatinine from measurements within 12 months before hospital

admission(15,16). If unavailable, we followed the KDIGO guidelines to estimate baseline serum

creatinine by back-calculating using the Modification of Diet in Renal Disease equation(17),

while assuming an estimated glomerular filtration rate 75 ml/min per 1.73 m². (14). We then

chose the lower of baseline or admission creatinine as the reference creatinine(18). Our specific

criteria for inclusion were adults aged 18 years or older upon admission, who developed sepsis

according to third international consensus definition(19,20) within 24 hours of admission to

intensive care unit (ICU)(21), and developed AKI within 48 hours after admission to ICU. We

considered only the first ICU admission for those patients with multiple admissions.

We excluded patients with a history of end stage kidney disease or kidney transplant, lack

of serum creatinine measurements within 24 hours after AKI onset, death or transfer out of the

ICU within 24 hours of AKI onset, or those with missing fluid administration values from ICU

admission to 24 hours after AKI onset.

Outcomes

The primary outcome of our study was early AKI reversal defined as the patient no

longer meeting KDIGO criteria for AKI at 24 hours of AKI onset(14). The secondary outcomes

included sustained AKI reversal, defined as maintaining AKI reversal for 48 hours or longer(22),

and major adverse kidney events by 30 days (MAKE30) was defined as a composite of in-

hospital death, new dialysis or persistent kidney dysfunction by hospital discharge or within 30

days of ICU admission, whichever occurred first (23). In consistence with previous literature,

persistent kidney dysfunction was defined as the final inpatient serum creatinine value as ≥200%

of reference creatinine(23).

Treatment

The treatment of interest in this study was the amount of IV fluids administered,

including both crystalloids and colloids, from the onset of AKI through the first 24 hours

afterward. We defined 'restrictive fluid strategy' as administrating less than 500mL of IV fluids

within this specified time frame.

Features

We extracted data on patient demographics, such as age, sex, and race/ethnicity, and for

vital signs, SOFA scores, vasopressor administration, use of mechanical ventilation, urine output,

net fluid balance from ICU admission to onset of AKI. We also extracted data for laboratory

values and administration of nephrotoxic medications(24) within the last 48 hours prior to AKI

onset. Additionally, we collected data on treatment - the amount of IV fluids administered from

the onset of AKI through the first 24 hours afterward. Physiologically improbable values were

removed based on inputs from content experts. For vital signs, laboratory values and SOFA

scores, we collected the highest, lowest and latest values when multiple values were present. We

only included features that were present in over 70% of the cohort. Missing data were imputed

using the multivariate imputation by chained equations (MICE) method(25).

Development of Policy Tree Approach

We used a novel, machine learning guided strategy ('Policy Tree') to identify critically ill

septic patients with AKI who would benefit from a restrictive fluid strategy. The development of

policy tree approach employed a dual machine learning methodology. In the first step, we

estimated individual treatment effects (ITE) to ascertain the impact restrictive fluid strategy in

the critical initial phase post-AKI onset at the individual patient level(26). Subsequently, we

applied the policy tree algorithm(27) to construct a decision tree(28).

Step 1 - Individual Treatment Effects Estimation: We utilized the causal forest(26) method to

estimate ITE within our development cohort. This method is a widely recognized quasi-

experimental approach for estimating treatment effects using observational data, as opposed to

conducting actual experiments. The causal forest uniquely targets the prediction of unit-level

conditional average treatment effects, focusing on maximizing the variance in treatment effects

between nodes rather than minimizing prediction error. This process involves two critical steps to

ensure accuracy and computational efficiency. Initially, it identifies optimal splits that maximize

the expected difference in treatment effects. Following that, during the prediction phase, it

estimates treatment effects by aggregating data from similar observations within the forest's

leaves.

Step 2 - Policy Tree Algorithm: We then used the policy tree algorithm(27) to identify patients

who would benefit in terms of early AKI reversal by adhering to restrictive fluid strategy. This

algorithm constructs a hierarchical model that categorizes patients based on similar ITE within

the same action node and distinct ITE across different action nodes. It considers ITE, relevant

features for policy tree construction, the depth of the tree, and the minimum number of

observations per node. The algorithm iteratively refines the feature splits to maximize the

variance in ITE.

Statistical Analysis

We expressed continuous features as mean and standard deviation, while categorical

features as proportions. We examined the differences across groups using bivariate analyses,

including analysis of variance (ANOVA) for continuous variables and chi-square tests for

categorical variables, with a P value of < .05 considered statistically significant across all

statistical tests.

We then used logistic and linear regression models to assess the impact of adhering to

personalized recommendation for restrictive fluid strategy on early AKI reversal, sustained AKI

reversal, and MAKE30. We adjusted these regression models for age, sex, race, reference serum

creatinine, SOFA score at the time of sepsis onset, AKI stage at the time of AKI onset, and net

fluid balance between ICU admission and AKI onset for each outcome.

All statistical analyses were performed using R software, version 4.3.0(29). The study

received approval from the Institutional Review Board at the Icahn School of Medicine at Mount

Sinai (approval no. 19-00951).

RESULTS:

Study Population

Our study included 12,826 patients in the Medical Information Mart for Intensive Care IV

(MIMIC-IV) as the development cohort, and 2,044 patients in the Salzburg Intensive Care

database (SICdb) as the external validation cohort. The average age in the development cohort

was 67.1 ± 15.9 years with 58.0% males. The average age in the external validation cohort was

66.9 ± 15.2 years with 62.7% males. The baseline characteristics are shown in **Table 1** and **Table**

E1 in the online data supplement.

Policy Tree for Restrictive Fluid Strategy in Critically Ill Septic Patients with AKI

265   Our policy tree identifies patients with AKI and sepsis who are likely to benefit from a

restrictive fluid strategy, defined as administering less than 500mL of IV fluids within 24 hours

of AKI onset (**Fig. 1**). The key determinants identified for early AKI reversal were urine output,

net fluid balance, systolic blood pressure (SBP), heart rate, oxygen saturation (SpO2), partial

pressure of oxygen (pO2), partial pressure of carbon dioxide (pCO2), hematocrit, platelet, white

blood cell (WBC) count, mean corpuscular hemoglobin concentration (MCHC), creatinine,

weight, and mechanical ventilation. The primary decision point in the policy tree was based on

the urine output between ICU admission and onset of AKI.

274   The policy tree suggested benefit from restrictive fluid strategy after development of AKI

among 6,937 (54.1%) patients in the development cohort and 1,363 (66.7%) patients in the

external validation cohort. The baseline characteristics of these patients are shown in Table 1 and

Supplementary Table S1. Among the patients identified to benefit from restrictive fluid therapy,

only 1,057 (15.2%) patients in development cohort and 87 (6.4%) patients in external validation

cohort received restrictive fluid therapy. Among patients identified to benefit from restrictive

fluid strategy, those that received restrictive fluids were older, with lower net fluid balance and

higher urine output from ICU admission to AKI in both development and external validation

cohort (**Table 2 and Table E2** in the online data supplement).

Outcomes

Primary Outcome: In both development and external validation cohorts, patients suggested by

policy tree to benefit from a restrictive fluid strategy who received restrictive fluids had

significantly higher rates of early AKI reversal in comparison to those that were suggested to

have a benefit from restrictive fluids but did not receive them – 47.1% vs. 35.7%; p<0.001 in

development cohort; 47.1% vs. 31.7%; p=0.004 in external validation cohort (**Fig. 2a**). On

unadjusted analysis, restrictive fluid strategy among the patients identified to benefit from

restrictive fluids, was associated with significantly greater odds of early AKI reversal in both

development (OR 1.60; 95% CI: 1.41 – 1.83) and external validation (OR 1.92; 95% CI: 1.24 –

2.97) cohorts (**Fig. 2b**). This effect was consistent in adjusted analysis where restrictive fluid

strategy among patients suggested to benefit from restrictive fluids was associated with greater

odds of early AKI reversal in both development (OR 1.63; 95% CI: 1.41 – 1.88) and external

validation cohorts (OR 1.87; 95% CI: 1.18 – 2.97) (**Fig. 2b**). In comparison, in both development

and external validation cohorts, patients identified to have no benefit from a restrictive fluid

strategy did not show any improvement in outcomes when they received restrictive fluids (**Fig.**

2a and 2b).

Secondary Outcomes: Among patients identified by the policy tree to benefit from a restrictive

fluid strategy, both the development and external validation cohorts showed that those who

received restrictive fluids had higher rates of sustained AKI reversal and lower rates of MAKE30

compared to those who did not receive restrictive fluids (**Fig. 2a**). In the external validation

cohort, among patients identified to benefit from restrictive fluids, 28.7% of those who received

restrictive fluids achieved sustained AKI reversal, compared to only 17.5% of those who did not

receive them (p=0.013). Additionally, only 23.0% of patients who received restrictive fluids

developed MAKE30, compared to 37.1% of those who did not receive them (p=0.011). In the

unadjusted analysis of the external validation cohort, use of restrictive fluids among patients

identified to benefit from a restrictive fluid strategy was associated with a significantly higher

odds sustained AKI reversal (OR 1.90; 95% CI: 1.17 – 3.10) and lower odds of developing

MAKE30 (OR 0.51; 95% CI: 0.30 – 0.84). This effect remained consistent in the adjusted

analysis, where a restrictive fluid strategy among patients identified to benefit from it was

associated with significantly higher odds of sustained AKI reversal (OR 1.77; 95% CI: 1.06 –

2.94) and lower odds of MAKE30 (OR 0.54; 95% CI: 0.31 – 0.84). Patients identified as not

deriving any benefit from restrictive fluid strategy showed no benefit from receiving restrictive

fluids in both adjusted and unadjusted analyses (**Fig. 2a and 2b**).

DISCUSSION:

In this study we have developed and validated a novel, data-driven, causal machine

learning strategy to identify critically ill patients with sepsis who develop AKI and would benefit

from a restrictive fluid strategy. We show that among patients predicted to benefit from and

administered restrictive fluids, there were increased odds of early AKI reversal and sustained

AKI reversal, alongside lower odds of MAKE30, even after adjusting for confounders.

Administration of IV fluids to improve cardiac output and consequently kidney blood

flow, has been a cornerstone of therapy for AKI. This is based on the assumption that decrease in

kidney blood flow is a major driver of AKI (30), However, there are 3 major observations which

contradict this hypothesis.

First, even though fluid administration may increase cardiac output and renal blood flow,

it does not lead to improvement in renal oxygen delivery or renal microvascular

oxygenation(31,32). Second, fluid bolus does not always increase urine output. In a prospective,

multicenter, observational study including 5 ICUs where patients with oliguria received IV fluids,

improvement in urine output was seen in only half of the patients(4). Third, kidney blood flow is

not decreased in sepsis(33). Instead, the pathogenesis of AKI in critically ill patients includes a

complex interplay of inflammatory mediators(34-36), microcirculatory dysfunction(37) and

metabolic reprogramming(38,39). These result in direct tubular injury, which is not reversible

with administration of IV fluids.

IV fluid administration can lead to volume overload, often seen in AKI patients, and is

associated with higher morbidity and mortality especially in AKI patients (40,41). This excess

fluid can cause interstitial edema(42,43), impaired blood flow and organ dysfunctions. Fluid

overload also damages the endothelial glycocalyx layer which is crucial for vascular homeostasis

and permeability. Inflammatory mediators in sepsis themselves lead to glycocalyx degradation, a

process which is exacerbated by IV fluid resuscitation(44). This glycocalyx damage increases

local inflammation, tissue edema and further end organ injury including acute respiratory distress

syndrome (ARDS) and AKI(45). Fluid overload is also a known risk-factor for development of

intra-abdominal hypertension(46), which further contributes to worsening AKI (47).

Thus, there is an increasing focus on minimizing the use of IV fluids in critically ill

patients. A randomized study comparing conservative and usual fluid therapy in patients with

ARDS found no difference in 60-day mortality(8). However, the conservative group had

improved oxygenation index, lung injury score, lower plateau pressures, increased number of

ventilator free days and ICU free days. Studies in patients with sepsis have also found a shorter

duration of mechanical ventilation and a trend towards lower mortality for patients managed with

conservative fluid strategy (48).

The REVERSE-AKI trial directly evaluated the role of restrictive fluid therapy for

management of AKI(10). This multicenter, randomized, controlled study enrolled adult, critically

ill patients with AKI not requiring dialysis. The trial aimed to attain a negative fluid balance in

the intervention arm following randomization. By 24 hours, the restrictive fluid group had a

cumulative fluid balance of -416mL vs 409mL in the usual care group (p<0.001). At 72 hours,

this balance was -1080mL vs 61mL (p=0.03). The trial found that the restrictive fluid group had

lower dialysis rates (13% vs 30%; p=0.04) and a trend towards lower duration of AKI (median 2

days vs 3 days; p=0.07). This trial demonstrated that restrictive fluid management in AKI is

feasible and may improve outcomes. Building on this, our study identifies critically ill septic

patients with AKI who would benefit from restrictive fluid therapy. We used Causal Forest Tree

(26) and Policy Tree (27) algorithms, two cutting-edge causal machine learning techniques to

develop a data driven approach to identify these patients. We show that when identified using

this approach, patients who do get restrictive fluids have much higher rates of both early AKI

and sustained AKI reversal, and lower rates of MAKE30. Validation of this approach in an

external database is a significant strength of this study.

In our study, we employed quasi-experimental methods to identify the impact of

restricted fluid intake on SA-AKI patients, focusing on quantifying those who benefit from such

intervention without conducting an actual experiment. Traditional statistical approaches, such as

propensity score-based methods, are often unsuitable for individual-level analysis. To address

this, machine learning techniques, including the Class Transformation Method (49) – which

converts the problem into a standard classification task by creating a new target variable

representing the difference in outcomes between treated and control groups – and the Two-Model

Approach (50) – where separate models for treated and control groups are built, and uplift is

calculated by the difference in predicted outcomes – are widely used. However, these methods

can be limited by issues such as imbalanced treatment assignments and insufficient sample sizes.

In contrast, the causal forest algorithm used in our study directly models individualized treatment

effects by analyzing the difference in sample average outcomes between treated and untreated

observations, thereby mitigating the limitations associated with the class transformation and two-

model approaches.

While estimating individual treatment effects (ITE) is an important step, it alone is not enough for developing a data-driven approach to identify patients who may benefit from restrictive fluid intake. Prior literature has categorized patients based on quartiles of individual treatment effects (51). However, this approach may not provide sufficient insights beyond the initial estimation, limiting its translation into real-time clinical practice. In this study, we employed a policy tree algorithm on the ITE that uses a decision tree-based approach. This data driven utilization of ITE not only identifies specific patients who are likely to benefit most from restrictive fluid intake but also provides a decision tree that offers explainability of the decision process. The branches and nodes of the tree help provide a more intuitive understanding of the physiological factors involved, enhancing the algorithm's potential for practical application in clinical practice.

It is important to acknowledge the limitations of our study. First, this is a retrospective study and validation of this approach in prospective, randomized studies is important. Second, we chose the cut-off of 500mL for restrictive fluids based prior literature suggesting 500mL is the typical amount of fluid given during a fluid challenge(3), and was also the amount given in restrictive fluid groups in prior studies(9,52). However, future work could focus on different fluid cutoffs. Third, while we adjusted for potential confounders, unmeasured and residual confounding cannot be eliminated.

In conclusion, in this study using a causal learning approach we developed and validated a strategy to identify critically ill patients with AKI who would benefit from a restrictive fluid

strategy. This approach should be considered in future prospective, pragmatic trials to improve

outcomes of septic patients with AKI.

ACKNOWLEDGMENTS.

Publicly available datasets were analyzed in this study. The dataset used in this study,

MIMIC-IV, is available at https://physionet.org/content/mimiciv/, and the SICdb dataset is

available at https://physionet.org/content/sicdb/.

REFERENCES.

1. Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009;35(5):871-881.

2. Peerapornratana S, Manrique-Caballero CL, Gomez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int 2019;96(5):1083-1099.

3. Cecconi M, Hofer C, Teboul JL, Pettila V, Wilkman E, Molnar Z, et al. Fluid challenges in intensive care: the FENICE study: A global inception cohort study. Intensive Care Med 2015;41(9):1529-1537.

4. Legrand M, Le Cam B, Perbet S, Roger C, Darmon M, Guerci P, et al. Urine sodium concentration to predict fluid responsiveness in oliguric ICU patients: a prospective multicenter observational study. Crit Care 2016;20(1):165.

5. Casas-Aparicio GA, Leon-Rodriguez I, Hernandez-Zenteno RJ, Castillejos-Lopez M, Alvarado-de la Barrera C, Ormsby CE, Reyes-Teran G. Aggressive fluid accumulation is associated with acute kidney injury and mortality in a cohort of patients with severe pneumonia caused by influenza A H1N1 virus. PLoS One 2018;13(2):e0192592.

6. Raimundo M, Crichton S, Martin JR, Syed Y, Varrier M, Wyncoll D, Ostermann M. Increased Fluid Administration After Early Acute Kidney Injury is Associated with Less Renal Recovery. Shock 2015;44(5):431-437.

450   7.   Berthelsen RE, Perner A, Jensen AK, Jensen JU, Bestle MH. Fluid accumulation during

451   acute kidney injury in the intensive care unit. Acta Anaesthesiol Scand 2018;62(6):780-

452   790.

453   8.   National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N,

454   Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, et al. Comparison of two fluid-

455   management strategies in acute lung injury. N Engl J Med 2006;354(24):2564-2575.

456   9.   Meyhoff TS, Hjortrup PB, Wetterslev J, Sivapalan P, Laake JH, Cronhjort M, et al.

457   Restriction of Intravenous Fluid in ICU Patients with Septic Shock. N Engl J Med

458   2022;386(26):2459-2470.

459   10.   Vaara ST, Ostermann M, Bitker L, Schneider A, Poli E, Hoste E, et al. Restrictive fluid

460   management versus usual care in acute kidney injury (REVERSE-AKI): a pilot

461   randomized controlled feasibility trial. Intensive Care Med 2021;47(6):665-673.

462   11.   Johnson AEW, Bulgarelli L, Shen L, Gayles A, Shammout A, Horng S, et al. MIMIC-IV,

463   a freely accessible electronic health record dataset. Sci Data 2023;10(1):1.

464   12.   Rodemund N, Wernly B, Jung C, Cozowicz C, Kokofer A. Harnessing Big Data in

465   Critical Care: Exploring a new European Dataset. Sci Data 2024;11(1):320.

466   13.   von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative

467   S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)

468   statement: guidelines for reporting observational studies. Lancet 2007;370(9596):1453-

469   1457.

470   14.   KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International

471   Supplements 2012;2(1):1-138.

472   15.   Peerapornratana S, Priyanka P, Wang S, Smith A, Singbartl K, Palevsky PM, et al. Sepsis-

473   Associated Acute Kidney Disease. Kidney Int Rep 2020;5(6):839-850.

474   16.   Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, et al. Sepsis-

475   associated acute kidney injury: consensus report of the 28th Acute Disease Quality

476   Initiative workgroup. Nat Rev Nephrol 2023;19(6):401-417.

477   17.   Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to

478   estimate glomerular filtration rate from serum creatinine: a new prediction equation.

479   Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130(6):461-

480   470.

481   18.   Sakhuja A, Bataineh A, Dealmeida D, Bilderback A, Ambrosino R, Fuhrman DY, Kellum

482   JA. Creating a High-Specificity Acute Kidney Injury Detection System for Clinical and

483   Research Applications. Am J Kidney Dis 2021;78(5):764-766.

484   19.   Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.

485   The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

486   JAMA 2016;315(8):801-810.

487   20.   Moor M, Bennett N, Plecko D, Horn M, Rieck B, Meinshausen N, et al. Predicting sepsis

488   using deep learning across international sites: a retrospective development and validation

489   study. EClinicalMedicine 2023;62:102124.

490   21.   Takkavatakarn K, Oh W, Chan L, Hofer I, Shawwa K, Kraft M, et al. Machine learning

491   derived serum creatinine trajectories in acute kidney injury in critically ill patients with

492   sepsis. Crit Care 2024;28(1):156.

22.   Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, et al. Acute

kidney disease and renal recovery: consensus report of the Acute Disease Quality

Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 2017;13(4):241-257.

23.   Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, et al. Balanced

Crystalloids versus Saline in Critically Ill Adults. N Engl J Med 2018;378(9):829-839.

24.   Goswami E, Ogden RK, Bennett WE, Goldstein SL, Hackbarth R, Somers MJG, et al.

Evidence-based development of a nephrotoxic medication list to screen for acute kidney

injury risk in hospitalized children. Am J Health Syst Pharm 2019;76(22):1869-1874.

25.   Buuren Sv, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained

Equations inR. Journal of Statistical Software 2011;45(3):1–67.

26.   Wager S, Athey S. Estimation and Inference of Heterogeneous Treatment Effects using

Random Forests. Journal of the American Statistical Association 2018;113(523):1228-

1242.

27.   Athey S, Wager S. Policy Learning With Observational Data. Econometrica

2021;89(1):133-161.

28.   von Winterfeldt D, Edwards W. Decision trees. In: Decision Analysis and Behavioral

Research: Cambridge University Press; 1986. p. 63–89.

29.   *R: A Language and Environment for Statistical Computing* [computer program]. R

Foundation for Statistical Computing.

30.   Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004;351(2):159-169.

31.   Wan L, Bellomo R, May CN. A comparison of 4% succinylated gelatin solution versus

normal saline in stable normovolaemic sheep: global haemodynamic, regional blood flow

and oxygen delivery effects. Anaesth Intensive Care 2007;35(6):924-931.

32.   Legrand M, Mik EG, Balestra GM, Lutter R, Pirracchio R, Payen D, Ince C. Fluid

517   resuscitation does not improve renal oxygenation during hemorrhagic shock in rats.

518   Anesthesiology 2010;112(1):119-127.

519   33.   Di Giantomasso D, May CN, Bellomo R. Vital organ blood flow during hyperdynamic

520   sepsis. Chest 2003;124(3):1053-1059.

521   34.   Maiden MJ, Otto S, Brealey JK, Finnis ME, Chapman MJ, Kuchel TR, et al. Structure

522   and Function of the Kidney in Septic Shock. A Prospective Controlled Experimental

523   Study. Am J Respir Crit Care Med 2016;194(6):692-700.

524   35.   Wang Z, Holthoff JH, Seely KA, Pathak E, Spencer HJ, 3rd, Gokden N, Mayeux PR.

525   Development of oxidative stress in the peritubular capillary microenvironment mediates

526   sepsis-induced renal microcirculatory failure and acute kidney injury. Am J Pathol

527   2012;180(2):505-516.

528   36.   Seely KA, Holthoff JH, Burns ST, Wang Z, Thakali KM, Gokden N, et al. Hemodynamic

529   changes in the kidney in a pediatric rat model of sepsis-induced acute kidney injury. Am J

530   Physiol Renal Physiol 2011;301(1):F209-217.

531   37.   De Backer D, Donadello K, Taccone FS, Ospina-Tascon G, Salgado D, Vincent JL.

532   Microcirculatory alterations: potential mechanisms and implications for therapy. Ann

533   Intensive Care 2011;1(1):27.

534   38.   Gomez H, Kellum JA, Ronco C. Metabolic reprogramming and tolerance during sepsis-

535   induced AKI. Nat Rev Nephrol 2017;13(3):143-151.

536   39.   Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive,

537   endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet

538   2004;364(9433):545-548.

539   40.   Zhang L, Chen Z, Diao Y, Yang Y, Fu P. Associations of fluid overload with mortality and

540   kidney recovery in patients with acute kidney injury: A systematic review and meta-

541   analysis. J Crit Care 2015;30(4):860 e867-813.

542   41.   Hayashi Y, Shimazui T, Tomita K, Shimada T, Miura RE, Nakada TA. Associations

543   between fluid overload and outcomes in critically ill patients with acute kidney injury: a

544   retrospective observational study. Sci Rep 2023;13(1):17410.

545   42.   Patil VP, Salunke BG. Fluid Overload and Acute Kidney Injury. Indian J Crit Care Med

546   2020;24(Suppl 3):S94-S97.

547   43.   Hansen B. Fluid Overload. Front Vet Sci 2021;8:668688.

548   44.   Hippensteel JA, Uchimido R, Tyler PD, Burke RC, Han X, Zhang F, et al. Intravenous

549   fluid resuscitation is associated with septic endothelial glycocalyx degradation. Crit Care

550   2019;23(1):259.

551   45.   Sullivan RC, Rockstrom MD, Schmidt EP, Hippensteel JA. Endothelial glycocalyx

552   degradation during sepsis: Causes and consequences. Matrix Biol Plus 2021;12:100094.

553   46.   Vatankhah S, Sheikhi RA, Heidari M, Moradimajd P. The relationship between fluid

554   resuscitation and intra-abdominal hypertension in patients with blunt abdominal trauma.

555   Int J Crit Illn Inj Sci 2018;8(3):149-153.

556   47.   Suphatheerawatr N, Jaturapisanukul S, Prommool S, Kurathong S, Pongsittisak W. Intra-

557   abdominal hypertension among medical septic patients associated with worsening kidney

558   outcomes (IAH-WK study). Medicine (Baltimore) 2023;102(4):e32807.

559   48.   Shahnoor H, Divi R, Addi Palle LR, Sharma A, Contractor B, Krupanagaram S, et al. The

560   Effects of Restrictive Fluid Resuscitation on the Clinical Outcomes in Patients with

561    Sepsis or Septic Shock: A Meta-Analysis of Randomized-Controlled Trials. Cureus

562    2023;15(9):e45620.

563 49.  Jaskowski M, Jaroszewicz S. Uplift modeling for clinical trial data. ICML Workshop on

564    Clinical Data Analysis; 2012.

565 50.  Radcliffe NJ, Surry PD. Real-World Uplift Modelling with Significance-Based Uplift

566    Trees2011. Located at: Stochastic Solutions.

567 51.  Seitz KP, Spicer AB, Casey JD, Buell KG, Qian ET, Graham Linck EJ, et al.

568    Individualized Treatment Effects of Bougie versus Stylet for Tracheal Intubation in

569    Critical Illness. Am J Respir Crit Care Med 2023;207(12):1602-1611.

570 52.  Jessen MK, Andersen LW, Thomsen MH, Kristensen P, Hayeri W, Hassel RE, et al.

571    Restrictive fluids versus standard care in adults with sepsis in the emergency department

572    (REFACED): A multicenter, randomized feasibility trial. Acad Emerg Med

573    2022;29(10):1172-1184.

580   **FIGURE LEGENDS.**

582   **Figure 1.** Policy Tree for Restrictive Fluid Strategy in Septic Patients with Acute Kidney Injury.

585   **Figure 2.** Impact of restrictive fluid strategy among patients stratified by predicted benefit from

586   receipt of restrictive fluid strategy: a) Proportion, b) Odds ratio, i) In MIMIC-IV (Development

587   Cohort), ii) in SICdb (External Validation Cohort).

594 **TABLES.**

596 Table 1. Baseline Characteristics of Patients in Development (MIMIC-IV) and External

597 Validation (SICdb) Cohorts.

	Development cohort (MIMIC-IV)				External validation cohort (SICdb)			
	Identified to have no benefit from restrictive fluid strategy (N= 712)	Identified to benefit from restrictive fluid strategy (N= 6,223)	Total (N= 6,935)	p value	Identified to have no benefit from restrictive fluid strategy (N= 247)	Identified to benefit from restrictive fluid strategy (N= 1844)	Total (N= 2,091)	p value
Age, year, (mean±SD)	66.79 ± 15.90	67.38 ± 15.60	67.11 ± 15.74	0.033	64.87 ± 15.96	67.96 ± 14.74	66.93 ± 15.23	< 0.001
Gender - Male, n (%)	3359 (57.0%)	4075 (58.7%)	7434 (58.0%)	0.051	420 (61.7%)	861 (63.2%)	1281 (62.7%)	0.510
Baseline creatinine, mg/dL, (mean±SD)	1.32 ± 1.38	1.20 ± 1.07	1.26 ± 1.22	< 0.001	0.88 ± 0.18	0.87 ± 0.18	0.87 ± 0.18	0.781
AKI stage, n (%)				< 0.001				< 0.001
1	4647 (78.9%)	5925 (85.4%)	10572 (82.4%)		547 (80.3%)	1234 (90.5%)	1781 (87.1%)	
2	594 (10.1%)	608 (8.8%)	1202 (9.4%)		38 (5.6%)	51 (3.7%)	89 (4.4%)	
3	648 (11.0%)	404 (5.8%)	1052 (8.2%)		96 (14.1%)	78 (5.7%)	174 (8.5%)	
SOFA at the time of sepsis onset, (mean±SD)	4.40 ± 2.43	4.50 ± 2.41	4.45 ± 2.42	0.034	4.28 ± 2.01	4.25 ± 1.97	4.26 ± 1.98	0.721
Vasopressors[B], n (%)	2002 (34.0%)	3257 (47.0%)	5259 (41.0%)	< 0.001	455 (66.8%)	1022 (75.0%)	1477 (72.3%)	< 0.001
Vasopressors[B],	3.04 ±	3.81 ±	3.46 ±	<	5.76 ±	6.05 ±	5.95 ±	0.38

hours (mean±SD)	6.55	6.58	6.57	0.001	7.90	7.02	7.32	6
Mechanical ventilation[B], n (%)	2799 (47.5%)	4249 (61.3%)	7048 (55.0%)	< 0.001	268 (39.4%)	670 (49.2%)	938 (45.9%)	< 0.001
Mechanical ventilation[B], hours (mean±SD)	5.63 ± 8.80	6.12 ± 7.93	5.89 ± 8.34	< 0.001	4.09 ± 7.39	4.25 ± 6.48	4.19 ± 6.80	0.619
Nephrotoxic drugs administration [A], n (%)	1756 (29.8%)	2046 (29.5%)	3802 (29.6%)	0.689	215 (31.6%)	478 (35.1%)	693 (33.9%)	0.115

599 Abbreviation: AKI (acute kidney injury), SOFA (sequential organ failure assessment)

600 [A]: Measurements from the last 48 hours prior to AKI onset

601 [B]: Measurements from ICU admission to AKI onset

613 Table 2. Baseline Characteristics of Patients Identified to Benefit from Restrictive Fluids:

614 Development (MIMIC-IV) and External Validation (SICdb) cohorts.

	Development cohort (MIMIC-IV)				External validation cohort (SICdb)			
	Unrestricted fluid intake group (N=5,411)	Restricted fluid intake group (N=812)	Total (N=6,223)	p value	Unrestricted fluid intake group (N=1,302)	Restricted fluid intake group (N=542)	Total (N=1844)	p value
Age, year, (mean±SD)	67.14 ± 15.61	68.75 ± 15.49	67.38 ± 15.60	0.002	67.97 ± 14.78	67.76 ± 14.32	67.96 ± 14.74	0.897
Gender - Male, n (%)	3445 (58.6%)	630 (59.6%)	4075 (58.7%)	0.537	803 (62.9%)	58 (66.7%)	861 (63.2%)	0.485
Baseline creatinine, mg/dL, (mean±SD)	1.17 ± 0.97	1.37 ± 1.49	1.20 ± 1.07	< 0.001	0.87 ± 0.18	0.88 ± 0.18	0.87 ± 0.18	0.669
AKI stage, n (%)				< 0.001				0.884
1	5073 (86.3%)	852 (80.6%)	5925 (85.4%)		1154 (90.4%)	80 (92.0%)	1234 (90.5%)	
2	487 (8.3%)	121 (11.4%)	608 (8.8%)		48 (3.8%)	3 (3.4%)	51 (3.7%)	
3	320 (5.4%)	84 (7.9%)	404 (5.8%)		74 (5.8%)	4 (4.6%)	78 (5.7%)	
SOFA at the time of sepsis onset, (mean±SD)	4.62 ± 2.46	3.83 ± 1.99	4.50 ± 2.41	< 0.001	4.28 ± 1.99	3.79 ± 1.60	4.25 ± 1.97	0.026
Vasopressors[B], n (%)	3075 (52.3%)	182 (17.2%)	3257 (47.0%)	< 0.001	967 (75.8%)	55 (63.2%)	1022 (75.0%)	0.009
Vasopressors[B], hours (mean±SD)	4.19 ± 6.70	1.74 ± 5.38	3.81 ± 6.58	< 0.001	6.13 ± 6.98	4.96 ± 7.61	6.05 ± 7.02	0.134
Mechanical ventilation[B], n (%)	3740 (63.6%)	509 (48.2%)	4249 (61.3%)	< 0.001	629 (49.3%)	41 (47.1%)	670 (49.2%)	0.695
Mechanical ventilation[B], hours (mean±SD)	6.28 ± 7.90	5.22 ± 8.00	6.12 ± 7.93	< 0.001	4.26 ± 6.46	4.08 ± 6.79	4.25 ± 6.48	0.801
Nephrotoxic drugs administration[A], n (%)	1602 (27.2%)	444 (42.0%)	2046 (29.5%)	< 0.001	451 (35.3%)	27 (31.0%)	478 (35.1%)	0.415

616   Abbreviation: AKI (acute kidney injury), SOFA (sequential organ failure assessment)

617   [A]: Measurements from the last 48 hours prior to AKI onset

618   [B]: Measurements from ICU admission to AKI onset

623   **FIGURES.**

625   **Figure 1.**

Figure 2.